EVOQ Therapeutics has entered into a Collaboration and Licence Agreement with Sanofi.

The partnership focuses on advancing EVOQ’s proprietary NanoDisc technology, which aims to restore the body’s natural immune tolerance mechanisms. 

This platform has the potential to develop disease-specific therapies for autoimmune conditions such as coeliac disease, type 1 diabetes, myelin oligodendrocyte glycoprotein (MOG) antibody disease, rheumatoid arthritis, and lupus.

Existing treatments largely manage symptoms rather than address the root cause — the breakdown of immune tolerance leading to the destruction of healthy tissues. 

EVOQ’s NanoDisc technology seeks to overcome this by re-establishing immune tolerance to enable curative outcomes.

EVOQ stands to receive more than USD 500 million in upfront, preclinical, development, and sales milestone payments, along with tiered royalties on future product sales.

Under the agreement, EVOQ and Sanofi will collaborate on research activities, with Sanofi responsible for global development and commercialisation.

Source: prnewswire.com